Exhibit 99.4
Company PresentationApril 2021 A subsidiary of
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the “Company”) and its parent, Evogene Ltd. (“Evogene”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. 2
INTRODUCTION 3
4 Company Overview Canonic was established in early 2019 as a spin-off from Evogene (NASDAQ, TASE: EVGN) focusing on medical cannabisCanonic has an exclusive license to develop cannabis varieties using Evogene’s state-of-the-art computational genomics technologyDistinct advantage to tackle market challenges by mapping, decoding and stabilizing the cannabis genetics Breeding infrastructure among the biggest in Israel and unique proprietary knowhow First generation varieties expected to produce premium quality products to connect the company with the patients and market Product launch expected at early 2022- the company is evaluating its first-generation varieties with licensed growers and in preparation for commercial cultivationCompany products expected to be launched under the “Canonic” brand in Israel followed by the EU and NA with local partners Next generation products expected to focus on 2 major medical indications, pain and inflammation that are >60% of the medical market* *Company estimate, based on data published by Israeli Health Ministry regarding number of medical cannabis users in Israel
OUR VISION 5 We are here because genetics can make cannabis much more effective Commercialize effective, precise and stable medical cannabis products, based on novel cannabis varieties, for optimized therapeutic impact
Guy Adler Product manager & business development Team 6 Dr. Arnon HeymanCEO Dr. Inbal Dangoor VP R&D Yoanatan WegmanAgronomist Dr. Michi BrogPlant breeder Elad BonjakTechnician Ido ZingerPropagation
Directors and Advisory Board 7 Ofer Haviv Chairman of the board Board of directors Evogene President & CEO Raanan CohenBusiness strategy Former CEO Koor industries Dr. Yossi TamCannabinoid clinical research Director, Multidisciplinary Center for Cannabinoid Research of the Hebrew university Dr. Yariv BrotmanPlant metabolic pathways Ben Gurion University & Max Planck institute of Molecular Plant Physiology Dorit KreinerFinance Evogene CFO Nirit ElyovichMarketing strategy Senior marketing specialist with over 20 years of B2C experience in various markets Shai LeviatovPlant breeding Commercial varieties breeding for more than 30 years in top leading multinational seeds companies Adv. Itay Rosenfeld Business strategy Advisors Cannabis entrepreneur and former BOD member of Intelicanna (TLV: INTL)
8 Global Cannabis Market Medical cannabis is >60% of the global market Global Spending by Region (In $B) 42.7 38.3 32.7 26.5 20.6 14.7 10.2 CAGR of 27%
Market Challenges & The Opportunity THE CHALLENGES 9 SPECIFICITY Significant knowledge gap prevents matching active compounds to medical indications YIELD More active compounds and income per sq foot STABILITY Substantial variationswithin varieties produceinconsistent products andtherefore inconsistent results THE OPPORTUNITY- With state-of-the-art plant genomic expertise Canonic can solve major market challenges
From Plant Genetics – To Medical Cannabis Products 10 Plant genetic knowhow is the basis for development of premium Cannabis varieties Premium varieties lead to novel medical Cannabis products addressing market challenges
Technology 11
Proven Capabilities Along The Development Value Chain 12 The only company in Israel holding computational genomics capabilities and the full plant infrastructure to execute Large genetic & breeding collections Propagation farm State of the art data collection tools Fully equipped labs & tissue culture rooms Advanced-breeding facility State of the art computational genomics
The Genomic Power – Trait Improvement 13 The potential – improving plant traits through genomic elements Cultured Maze Wild Maze Example- wild corn went through numerous genomic changes before it became a commercial crop. Today corn is the food market basis for the entire world. The challenge: How can we connect genes to traits?How can we shorten the development time?
Computational Genomics Combining deep scientific knowhow with Big Data and AI technology to tailor the plant genetic for improvement of plant traits and development of unique cannabis products 14 When Genomics Meets Computational Biology BIG DATA Genomics AI
Big Data & AI transforming Data to Knowhow 15 MetaYield+ Precise+ Cannabis tailored unique database BIG DATA AI Computational genomics tools Plant genomics database with >109 data points on > 200 plants Proprietary Cannabis genomic & chemical data on > 800 lines from 50 sources Pre-clinical data
16 Canonic Holds Unique Knowhow in Plant Genetics Controlling genetics controlling plant traits improving cannabis type & quality Plant traits under development at Canonic Medical effect Active compounds Trichome density Inflorescence size Plant architecture 1 3 5 7 2 4 6 8 9 10 Increasing target compound Inflorescence density Reducing target compound Disease resistance Time to flower
PRODUCTS 17
Variety Families Under Development 18 Increased compounds per area [e.g. Dwarf & early flowering] Increased compounds per plant[e.g. Increased trichomes prevalence] MetaYield+ Stable enhancement of total plant compounds.Focus on agronomic and consumer traits. Compound profile focus [e.g. CBG, CBC] Medical indication focus [e.g. Pain & Inflammation] Precise+ Stable enhancement of specific active compoundsFocus on therapeutic traits First product launch expected in 2022 First product launch expected in 2023
MetaYield+ : First Commercial Varieties 19 Canonic expects to commercialize its first varieties during 2022 High THC Variety name- NOA series Status:pre- commercial Expected launch in Israel:early 2022 Relevant market segment:T20/C4** High yield Big inflorescence Dense trichomes Target markets: Israel ($250M*) EU ($500M*) *Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020. ** THC 20%, CBD 4% 19
Precise+ : Next Generation Varieties 20 Indication: Inflammation Product 1 Pre-clinical study: Hadassah medical center Status: product development Expected launch in Israel: 2023 Indication: Pain Product 2 Pre-clinical study: Migal research center Status: product development Expected launch in Israel: 2023 Target market size:* Israel $280 M, EU $750M Target market size:* Israel $115M, EU $300M *Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.
Next Generation Products 21 Collaboration With Tikun Olam-Cannbit as Part of Precise+ Product Development Compound profile focus Medical indication focus Precise+ Stable enhancement of specific active compoundsFocus on therapeutic traits
22 Business model
Cannabis Value Chain FROM GENOMICS TO PRODUCT 23 VarietiesDevelopment R&D Facilities Distribution RegionalDistributors Seeds & SeedlingProduction PropagationFarms Sales& Marketing Pharmacies & WebPlatforms Packaging, Extraction &Formulation Manufacturers CannabisCultivation Cultivators Patients ACTIVITY
Quickly and cost effectively reach the end user, by leveraging proprietarygenomic expertise and outsourcing downstream elements of the value chain 24 Patients VarietiesDevelopment Active R&D Facilities Distribution RegionalDistributors Seeds & SeedlingProduction Active PropagationFarm Sales& Marketing Pharmacies & WebPlatforms Extraction &Formulation Extraction &Formulation CannabisCultivation Cultivators ACTIVITY agreement signed Canonic in the Cannabis Value Chain agreement signed agreement signed Service providers
Value Creation – Short Term Milestones 25 2021- pre commercial MetaYield – reach 1st commercial variety; sign production and distribution agreements in anticipation for commercialization in 2022Precise - identify specific lines that exhibit distinct effect in model systems for reducing pain or inflammation MetaYield - commercial launch and initial sales of 1st product in IsraelPrecise - reach 1st commercial variety for reducing pain or inflammation as preparation for commercial launch in 2023 2022- commercial
Anticipated Commercial Milestones (5y) 26 Establishment POC & Go-to-Market MetaYield+ Pre-Commercial MetaYield+ Commercial Precise+ market entry Market entry N. America 2019 2020 2021 2022 Market establishment 1 2 3 4 5 6 Infrastructure, seed collection & cultivation Go to Market Initial sales 2023 2024 2025 Target Markets IL IL, EU N. America
Summary 27
Cutting-Edge Technology Addressing Market Challenges 28 Stability Specificity Yield Reduced genetic variation Diverse extracts for pre-clinical assays Increased trichome density
Summary 29 Canonic aims to develop novel varieties through a unique genomic approach and commercialize medical grade Cannabis Exclusive access to computational genomics technology Commercial partners in place for cultivation, production and distribution (IL) Product launch expected in 2022 Infrastructure in place – from seed to sale Leading academic partnerships for unique variety development
THANK YOU